secwatch.observer — SEC 8-K summary
======================================

Issuer:     Oruka Therapeutics, Inc. (ORKA)
CIK:        0000907654
Form:       8-K
Filed at:   2024-11-18T23:59:59+00:00
Accession:  0001213900-24-099645
Event type: other
Sentiment:  neutral
Materiality: 0.15
Item codes: 5.07
LLM model:  deepseek-v4-flash:cloud@v2

Oruka shareholders approve Series A conversion and adjournment proposals
------------------------------------------------------------------------

- 30,598,476 shares voted for Series A conversion; 6,026 against; 1,089 abstaining; no broker non-votes.
- 29,294,720 shares voted for adjournment proposal; 1,309,805 against; 1,066 abstaining.
- Both proposals approved at special meeting held November 14, 2024.
- Conversion involves Series A Non-Voting Convertible Preferred Stock issued September 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/907654/000121390024099645/0001213900-24-099645-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/907654/000121390024099645/ea0221692-8k_oruka.htm
  HTML page:      https://secwatch.observer/filing/0001213900-24-099645

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer